Cargando…

PReS-FINAL-2152: Biomarkers as predictors of early inactive disease in children with juvenile idiopathic arthritis

Detalles Bibliográficos
Autores principales:	Lavric, M, Weinhage, T, Klotsche, J, Horneff, G, Haas, JP, Minden, K, Foell, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044080/ http://dx.doi.org/10.1186/1546-0096-11-S2-P164

Ejemplares similares

PReS-FINAL-2150: Antiocular antibodies in children with juvenile idiopathic arthritis-associated uveitis
por: Walscheid, K, et al.
Publicado: (2013)

Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study
por: Tappeiner, Christoph, et al.
Publicado: (2018)

PReS-FINAL-2043: Cardiac involvement in juvenile idiopathic arthritis
por: Rossetto, E, et al.
Publicado: (2013)

PReS-FINAL-2031: Hyaluronic acid is a marker of active arthritis, but not systemic inflammation in systemic juvenile idiopathic arthritis
por: Hugle, B, et al.
Publicado: (2013)

PReS-FINAL-2097: Evaluation of gait in children with juvenile idiopathic arthritis
por: Baydogan, SN, et al.
Publicado: (2013)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study
por: Heiligenhaus, Arnd, et al.
Publicado: (2019)

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)
por: De Benedetti, F, et al.
Publicado: (2013)

PReS-FINAL-2145: MRP8/14 serum complexes as predictor of response to etanercept treatment in juvenile idiopathic arthritis
por: Anink, J, et al.
Publicado: (2013)

PReS-FINAL-2165: Pharmacogenetic determinants of response to methotrexate in juvenile idiopathic arthritis
por: Pastore, S, et al.
Publicado: (2013)

PReS-FINAL-2081: Accelerometer-assessed daily activity in juvenile idiopathic arthritis
por: Noergaard, M, et al.
Publicado: (2013)

PReS-FINAL-2109: Genetic variations in patients with juvenile idiopathic arthritis and uveitis
por: Reinards, TH, et al.
Publicado: (2013)

PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2013)

PReS-FINAL-2018: The P53 gene polymorphisms and juvenile idiopathic arthritis
por: Kozhevnikov, A, et al.
Publicado: (2013)

PReS-FINAL-2048: Treatment with methotrexate plus leflunomide for juvenile idiopathic arthritis
por: Quesada-Masachs, E, et al.
Publicado: (2013)

PReS-FINAL-2007: Adolescent clinic for young patients with juvenile idiopathic arthritis
por: Sørensen, SK
Publicado: (2013)

PReS-FINAL-2060: The role of stress factors in the onset of juvenile idiopathic arthritis
por: Stepanenko, N, et al.
Publicado: (2013)

PReS-FINAL-2182: The role of murine rage in innate immune responses and inflammation: a systematic approach
por: Wirth, T, et al.
Publicado: (2013)

PReS-FINAL-2104: Disease course and predictors of outcome in systemic onset juvenile idiopathic arthritis
por: Soponkanaporn, S, et al.
Publicado: (2013)

The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort
por: Sengler, Claudia, et al.
Publicado: (2015)

PReS-FINAL-2263: Progressive pseudorheumatoid dysplasia in differential diagnosis of juvenile idiopathic arthritis
por: Vrtíková, E, et al.
Publicado: (2013)

PReS-FINAL-2077: Lung function evaluation in a juvenile idiopathic arthritis cohort
por: Machado Vaz, I, et al.
Publicado: (2013)

PReS-FINAL-2061: Abatacept in therapy of juvenile idiopathic arthritis in real clinical practice
por: Arsenyeva, SV, et al.
Publicado: (2013)

PReS-FINAL-2066: Use of chiropractic care in danish children with juvenile idiopathic arthritis
por: Kuhn, KS, et al.
Publicado: (2013)

PReS-FINAL-2089: Temporomandibular joint involvement and quality of life in juvenile idiopathic arthritis
por: Frid, P, et al.
Publicado: (2013)

PReS-FINAL-2052: Costs of biologics in juvenile idiopathic arthritis: past, present and future
por: Prince, FH, et al.
Publicado: (2013)

PReS-FINAL-2155: Genetic variability of methotrexate transporters in patients with juvenile idiopathic arthritis
por: Zajc Avramovič, M, et al.
Publicado: (2013)

PReS-FINAL-2170: Work disability in adult patients with juvenile idiopathic arthritis (JIA)
por: Goldenstein-Schainberg, C, et al.
Publicado: (2013)

PReS-FINAL-2138: Abatacept (orencia) in treatment of different types of juvenile idiopathic arthritis
por: Zholobova, ES, et al.
Publicado: (2013)

PReS-FINAL-2036: Proteins of the lectin pathway of the complement system in juvenile idiopathic arthritis
por: Petri, C, et al.
Publicado: (2013)

PReS-FINAL-2084: Prevalence of cervical spine involvement in children with juvenile idiopathic arthritis
por: Semolič, N, et al.
Publicado: (2013)

Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
por: Klotsche, Jens, et al.
Publicado: (2021)

PReS-FINAL-2133: Drug survival and switching of biological agents in systemic juvenile idiopathic arthritis
por: Woerner, A, et al.
Publicado: (2013)

PReS-FINAL-2160: Intestinal microbiome in polyarticular juvenile idiopathic arthritis: a pilot study
por: Hissink Muller, PC, et al.
Publicado: (2013)

PReS-FINAL-2099: Assessing the standards of oral health in children and adolescents with juvenile idiopathic arthritis
por: Trehane, SJ, et al.
Publicado: (2013)

PReS-FINAL-2100: Methotrexate treatment affects effector, but not regulatory T cells in juvenile idiopathic arthritis
por: Vastert, S, et al.
Publicado: (2013)

PReS-FINAL-2110: Tocilizumab for patients with oligoarticular juvenile idiopathic arthritis refractory to conventional therapy
por: Sato, T, et al.
Publicado: (2013)

IL-6 blockade in systemic juvenile idiopathic arthritis – achievement of inactive disease and remission (data from the German AID-registry)
por: Bielak, M., et al.
Publicado: (2018)

Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany
por: Heiligenhaus, Arnd, et al.
Publicado: (2020)

PReS-FINAL-2068: S100 A8/A9 serum levels reflect disease activity in juvenile idiopathic arthritis-associated uveitis
por: Walscheid, K, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ak2aiiobiprmsohk0rm3g72p2o